Latvija -
latviešu -
Zāļu valsts aģentūra
baclofen sintetica 2 mg/ml šķīdums infūzijām
sintetica gmbh, germany - baklofēns - Šķīdums infūzijām - 2 mg/ml
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
rinvoq
abbvie deutschland gmbh & co. kg - upadacitinib - artrīts, reimatoīds - imūnsupresanti - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
oxybee
dany bienenwohl gmbh - skābeņskābes dihidrātu - ectoparasiticides lokālai lietošanai, t.sk. insekticīdi - bites - attīrīšanas varroosis (varroa destructor) medus bites (apis mellifera) , peru-bezmaksas kolonijas.
Latvija -
latviešu -
Zāļu valsts aģentūra
diclovit cietās kapsulas
g.l. pharma gmbh, austria - diclofenacum natricum, thiamini hydrochloridum, pyridoxini hydrochloridum, cyanocobalaminum - kapsula, cietā
Latvija -
latviešu -
Zāļu valsts aģentūra
ibuprofen jnx 400 mg apvalkotās tabletes
g.l. pharma gmbh, austria - ibuprofēns - apvalkotā tablete - 400 mg
Latvija -
latviešu -
Zāļu valsts aģentūra
ibuprofen lannacher 600 mg apvalkotās tabletes
g.l. pharma gmbh, austria - ibuprofēns - apvalkotā tablete - 600 mg
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
dany's bienenwohl
dany bienenwohl gmbh - skābeņskābes dihidrātu - ectoparasiticides for topical use, incl. insecticides, ectoparaciticides, insecticides and repellents - honey bees - attīrīšanas varroosis (varroa destructor) medus bites (apis mellifera) , peru-bezmaksas kolonijas.
Latvija -
latviešu -
Zāļu valsts aģentūra
salofalk 1000 mg ilgstošās darbības granulas
dr. falk pharma gmbh, germany - mesalazīns - ilgstošās darbības granulas - 1000 mg
Latvija -
latviešu -
Zāļu valsts aģentūra
salofalk 1,5 g ilgstošās darbības granulas
dr. falk pharma gmbh, germany - mesalazīns - ilgstošās darbības granulas - 1,5 g
Latvija -
latviešu -
Zāļu valsts aģentūra
salofalk 500 mg ilgstošās darbības granulas
dr. falk pharma gmbh, germany - mesalazīns - ilgstošās darbības granulas - 500 mg